FGA
CRBP icon

Fortis Group Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Fortis Group Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131 Hold
14
– – ﹤0.01% 598
2026
Q1 		$131 Hold
14
– – ﹤0.01% 564
2025
Q4 		$114 Hold
14
– – ﹤0.01% 562
2025
Q3 		$177 Hold
14
– – ﹤0.01% 511
2025
Q2 		$97 Hold
14
– – ﹤0.01% 511
2025
Q1 		$74 Hold
14
– – ﹤0.01% 483
2024
Q4 		$165 Hold
14
– – ﹤0.01% 484
2024
Q3 		$289 Hold
14
– – ﹤0.01% 470
2024
Q2 		$634 Hold
14
– – ﹤0.01% 462
2024
Q1 		$549 Sell
14
-14
-50% -$345 ﹤0.01% 476
2023
Q4 		$170 Buy
28
+14
+100% +$75 ﹤0.01% 438
2023
Q3 		$94 Buy
+14
New +$97 ﹤0.01% 436
2020
Q3 		$0 Buy
+15
New +$2.72K ﹤0.01% 452

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Fortis Group Advisors's CRBP Position: Q2 2026 in Review

Fortis Group Advisors held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 14 shares worth $131. The position accounts for ﹤0.01% of the portfolio, ranked #598.

Fortis Group Advisors first reported a position in CRBP in Q3 2020 and has held it in 13 quarters since. The position peaked at $634 in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Fortis Group Advisors held 14 shares of Corbus Pharmaceuticals worth $131 as of Q2 2026.
  • Fortis Group Advisors left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Fortis Group Advisors's portfolio in Q2 2026, its #598 holding.
  • Fortis Group Advisors first reported a position in Corbus Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
  • Fortis Group Advisors's Corbus Pharmaceuticals position peaked at $634 in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Fortis Group Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.